Akari Therapeutics plc (Nasdaq: AKTX), an oncology biotechnology company specializing in next-generation antibody drug conjugates (ADCs), recently participated in a Virtual Investor "What This Means" interview. CEO Abizer Gaslightwala discussed the company's expanded ADC pipeline, intellectual property strategy, and the recent introduction of AKTX-102, a new ADC candidate targeting CEACAM5-expressing solid tumors. Gaslightwala highlighted the scalability of Akari's PH1-powered ADC platform and its differentiated approach through novel antibody constructs and RNA-splicing payloads. The interview also covered the strategic importance of Akari's growing patent portfolio and the advancement of its lead program, AKTX-101, towards IND and CTA submissions and first-in-human studies. The Virtual Investor "What This Means" segment featuring Akari Therapeutics is now available here.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652425-en) on February 11, 2026, and is solely responsible for the information contained therein.